Immunochemotherapy in American Cutaneous Leishmaniasis: Immunological Aspects before and after Treatment

Memorias do Instituto Oswaldo Cruz

Volumn 96, Issue 1, 2001, Pages 89-98

  Toledo, V P C P ^a   Mayrink, W ^a   Gollob, K J ^a   Oliveira, M A P ^a   Da Costa, C A ^a   Genaro, O ^a   Pinto, J A ^a   Afonso, L C C ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

Human; Immunochemotherapy; Interferon ; Leishmaniasis

Indexed keywords

ANTIMONY; ANTIPROTOZOAL AGENT; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; MEGLUMINE; MEGLUMINE ANTIMONIATE; ORGANOMETALLIC COMPOUND; PARASITE ANTIGEN; PROTOZOAL VACCINE;

ADULT; ANIMAL; ARTICLE; BIOSYNTHESIS; CELLULAR IMMUNITY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOLOGY; LEISHMANIA; MALE; SKIN LEISHMANIASIS;

ADULT; ANIMALS; ANTIGENS, PROTOZOAN; ANTIMONY; ANTIPROTOZOAL AGENTS; CYTOKINES; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; INTERLEUKIN-10; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PROTOZOAN VACCINES;

EID: 0035221732     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02762001000100010     Document Type: Article

References (48)

1. Afonso, LCC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P 1994. The adjuvant effect of Interleukin-12 in a vaccine against Leishmania major. Science 263: 235-237.
2. Antunes CMF, Mayrink W, Magalhães PA, Costa CA, Melo MN, Michalick MSM, Williams P, Oliveira Lima A, Vieira JBF, Schettini APM 1986. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int J Epidemiol 15: 572-580.
3. Bacellar O, Brodskyn C, Guerreiro J, Barral-Netto M, Costa CH, Coffman RL, Johnson WD, Carvalho EM 1996. Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. J Infect Dis 173: 1515-1518.
4. Berger BJ, Fairlamb AH 1992. Interactions between immunity and chemotherapy in the treatment of the trypanosomiases and leishmaniases. Parasitology 105 (Suppl.): S71-S78.
5. Camargo EP 1964. Growth and differentiation in Trypanosoma cruzi. I. Origin of metacyclic trypanosomes in liquid medium. Rev Inst Med Trop São Paulo 6: 43-100.
6. Carvalho EM, Correia FD, Bacellar O, Almeida RP, Lessa H, Rocha H 1995. Characterization of the immune response in subjects with self-healing cutaneous leishmaniasis. Am J Trop Med Hyg 53: 273-277.
7. Convit J, Castellano PL, Rondón AJ, Pinardi ME, Ulrich M, Castés M, Bloom B, Garcia L 1987. Immunotherapy versus chemotherapy in localized cutaneous leishmaniasis. Lancet 1: 401-405.
8. Convit J, Ulrich M, Fernandez CT, Tapia FJ, Caceres-Dittmar G, Castes M, Rondon AJ 1993. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 87: 444-448.
9. Coutinho SG, da-Cruz AM, Bertho AL, Santiago MA, de Luca P 1998. Immunologic patterns associated with cure in human American cutaneous leishmaniasis. Braz J Med Biol Res 31: 139-142.
10. Coutinho SG, Oliveira MP, da Cruz AM, de Luca PM, Mendonça SC, Bertho AL, Soong L, McMahon-Pratt D 1996. T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure. Exp Parasitol 84: 144-155.
11. Cunha RMC, Hallack KA, Mayrink W 1994. Leishmaniose disseminada em paciente infcctado pelo virus HIV. Evolução clínico-morfológica atípica. Rev Soc Bras Med Trop 27: 389-401.
12. D'Andrea A, Aste-Amezaga M, Valiantc NM, Ma X, Kubin M, Trinchieri G 1993. Interleukin-10 inhibits human lymphocyte IFN-γ production by suppressing natural killer cell stimulatory factor/interleukin-12 synthesis in accessory cells. J Exp Med 178: 1041-1048.
13. da Costa CA, Toledo VPCP, Genaro O, Williams P, Mayrink W 1996. Montenegro skin test-evaluation of the composition and stability of the antigen preparation. Mem Inst Oswaldo Cruz 91: 193-194.
14. da Cruz AM, Conceição-Silva F, Bertho AL, Coutinho S 1994a. Leishmania - Reactive CD4+ and CD8+ T cells associated with cure of human cutaneous leishmaniasis. Infect Immun 62: 2614-2618.
15. da Cruz AM, Mayrink W, Filgueiras D, Coutinho S 1994b. Imunoquimioterapia em um paciente com leishmaniose mucocutânea e SIDA: Estudos imunológicos. Rev Soc Bras Med Trop 27: 388-389.
16. Etges R, Müller I 1998. Progressive disease or protective immunity to Leishmania major infection: the result of a network of stimulatory and inhibitory interactions. J Mol Med 76: 372-390.
17. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A 1991. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146: 3444-3451.
18. Genaro O, Toledo VPCP, Costa CA, Hermeto MV, Afonso LCC, Mayrink W 1996. Vaccine for prophylaxis and immunotherapy, Brazil. Clin Dermatol 14: 503-512.
19. Grogl M, Thomason TN, Franke ED 1992. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am J Trop Med Hyg 47: 117-126.
20. + lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci USA 88: 7011-7015.
21. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK 1993. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 177: 1505-1509.
22. Hermeto MV, Vieira-Dias D, Genaro O, Rotondo-Silva A, da Costa CA, Toledo VPCP, Michalick MSM, Williams P, Mayrink W 1994. Outbreak of cutaneous leishmaniasis in the Rio Doce Valley, Minas Gerais, Brazil. Mem Inst Oswaldo Cruz 89: 519-521.
23. Howard M, O'Garra A 1992. Biological properties of interleukin 10. Immunol Today 113: 198-200.
24. Kemp M 1997. Regulator and effector functions of T-cell subsets in human Leishmania infections. APMIS 105 (Suppl. 68): 5-33.
25. Locksley RM, Heinzel FP, Sadick MD, Holaday BJ, Gardner JrKD 1987. Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T-cell subsets. Ann Inst Pasteur/ Immunol 138: 744-749.
26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ 1951. Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275.
27. Marsden P 1985. Pentavalent antimonials: old drugs for new diseases. Rev Soc Bras Med Trop 18: 187-187.
28. Mattner F, Magram J, Ferrante J, Launois P, Di Padova K, Behin R, Gately MK, Louis JA, Alber G 1996. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 26: 1553-1559.
29. Mayrink W, Antunes CMF, da Costa CA, Melo MN, Dias M, Michalick MSM, Magalhães P, Oliveira Lima A, Williams P. 1986. Further trials of a vaccine against American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 80: 1001.
30. Mayrink W, da Costa CA, Magalhães PA, Melo MN, Dias M, Oliveira Lima A, Michalick MS, Williams P 1979. A field trial of a vaccine against American dermal leishmaniasis. Trans R Soc Trop Med Hyg 73: 385-387.
31. Mayrink W, Magalhães PA, Michalick MSM, da Costa CA, Oliveira Lima A, Melo MN, Toledo VPCP, Nascimento E, Dias M, Genaro O, Hermeto MV, Williams P 1992. Immunotherapy as a treatment of American cutaneous leishmaniasis: preliminary studies in Brazil. Parassitologia 34: 159-165.
32. Mayrink W, Michalick MSM, Melo MN, Williams P, Nascimento E, Magalhães PA, da Costa CA, Oliveira Lima A, Dias M 1991. Tratamento da leishmaniose tegumentar americana utilizando vacina. An Bras Dermatol 66: 55-59.
33. Mayrink W, Williams P, Magalhães PA, Melo MN, Dias M, Oliveira Lima A, Michalick MSM, Ferreira Carvalho E, Barros GC, Sessa PA, Alencar JTA 1985. An experimental vaccine against American dermal leishmaniasis: experience in the state of Espirito Santo, Brazil. Ann Trop Med Parasitol 79: 259-269.
34. Melby PC, Andrade-Narvaez FJ, Darnell BJ, Valencia-Pacheco G, Tryon VV, Palomo-Cetina A 1994. Increased expression of pro-inflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect Immun 62: 837-842.
35. Mendonça SC, Coutinho SG, Amendoeira RR, Marzochi MCA, Pirmez C 1986. Human cutaneous leishmaniasis (Leishmania b. braziliensis) in Brazil: lymphoproliferative responses and influence of therapy. Clin Exp Immunol 64: 269-276.
36. Mendonça SCF, de Luca PM, Mayrink W, Restom TG, Conceição-Silva F, da Cruz AM, Bertho AL, da Costa CA, Genaro O, Toledo VPCP, Coutinho SG 1995. Characterization of human T lymphocyte-mediated immune responses induced by a vaccine against American tegumentary leishmaniasis. Am J Trop Med Hyg 53: 195-201.
37. Mosmann TR, Moore KW 1991. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today: A49-A53.
38. Murray HW, Oca MJ, Granger AM, Schreiber, RD 1989. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J Clin Invest 83: 1253-1257.
39. Nabors GS, Afonso LCC, Farrell JP, Scott P 1995. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam. Proc Natl Acad Sci USA 92: 3142-3146.
40. Nascimento E, Mayrink W, da Costa CA, Michalick MSM, Melo MN, Barros GC, Dias M, Antunes CMF, Lima MS, Taboada DC, Liu TY 1990. Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses. Infect Immun 58: 2198-2203.
41. Peters BS, Fish D, Golden R, Evans DA, Bryceson AD, Pinching AJ 1990. Visceral leishmaniasis in HIV infection and AIDS: clinical features and response to therapy. Q J Med 77: 1101-1111.
42. Prussin C, Metcalfe DD 1995. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J Immunol Methods 188: 117-128.
43. Ribeiro-de-Jesus A, Almeida RP, Lessa H, Bacellar O, Carvalho EM 1998. Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res 31: 143-148.
44. + T cells subsets and induces early resistance to Leishmania major in mice. J Exp Med 178: 567-577.
45. Scott P 1989. The role of TH1 and TH2 cells in experimental cutaneous leishmaniasis. Exp Parasitol 68: 369-372.
46. Scott P 1991. IFN-γ modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J Immunol 147: 3149-3155.
47. Scott P, Trinchieri G 1995. The role of natural killer cells in host-parasite interactions. Curr Opinion Immunol 7: 34-40.
48. WHO - World Health Organization 1990. Control of the leishmaniases. Report of a WHO Expert Committee. WHO Tech Rep Ser 793: 1-158.